Erschienen in:
26.06.2019 | Peritoneal Surface Malignancy
Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative
verfasst von:
Adriana C. Gamboa, MD, Mohammad Y. Zaidi, MD, MS, Rachel M. Lee, MD, MSPH, Shelby Speegle, MA, Jeffrey M. Switchenko, PhD, Joseph Lipscomb, PhD, Jordan M. Cloyd, MD, Ahmed Ahmed, MD, Travis Grotz, MD, Jennifer Leiting, MD, Keith Fournier, MD, Andrew J. Lee, MD, Sean Dineen, MD, Benjamin D. Powers, MD, MS, Andrew M. Lowy, MD, Nikhil V. Kotha, BS, Callisia Clarke, MD, T. Clark Gamblin, MD, Sameer H. Patel, MD, Tiffany C. Lee, MD, Laura Lambert, MD, Ryan J. Hendrix, MD, Daniel E. Abbott, MD, Kara Vande Walle, MD, Kelly Lafaro, MD, Byrne Lee, MD, Fabian M. Johnston, MD, MHS, Jonathan Greer, MD, Maria C. Russell, MD, Charles A. Staley, MD, Shishir K. Maithel, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2020
Einloggen, um Zugang zu erhalten
Abstract
Background
No guidelines exist for surveillance following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal and colorectal cancer. The primary objective was to define the optimal surveillance frequency after CRS/HIPEC.
Methods
The U.S. HIPEC Collaborative database (2000–2017) was reviewed for patients who underwent a CCR0/1 CRS/HIPEC for appendiceal or colorectal cancer. Radiologic surveillance frequency was divided into two categories: low-frequency surveillance (LFS) at q6–12mos or high-frequency surveillance (HFS) at q2–4mos. Primary outcome was overall survival (OS).
Results
Among 975 patients, the median age was 55 year, 41% were male: 31% had non-invasive appendiceal (n = 301), 45% invasive appendiceal (n = 435), and 24% colorectal cancer (CRC; n = 239). With a median follow-up time of 25 mos, the median time to recurrence was 12 mos. Despite less surveillance, LFS patients had no decrease in median OS (non-invasive appendiceal: 106 vs. 65 mos, p < 0.01; invasive appendiceal: 120 vs. 73 mos, p = 0.02; colorectal cancer [CRC]: 35 vs. 30 mos, p = 0.8). LFS patients had lower median PCI scores compared with HFS (non-invasive appendiceal: 10 vs. 19; invasive appendiceal: 10 vs. 14; CRC: 8 vs. 11; all p < 0.01). However, on multivariable analysis, accounting for PCI score, LFS was still not associated with decreased OS for any histologic type (non-invasive appendiceal: hazard ratio [HR]: 0.28, p = 0.1; invasive appendiceal: HR: 0.73, p = 0.42; CRC: HR: 1.14, p = 0.59). When estimating annual incident cases of CRS/HIPEC at 375 for non-invasive appendiceal, 375 invasive appendiceal and 4410 colorectal, LFS compared with HFS for the initial two post-operative years would potentially save $13–19 M/year to the U.S. healthcare system.
Conclusions
Low-frequency surveillance after CRS/HIPEC for appendiceal or colorectal cancer is not associated with decreased survival, and when considering decreased costs, may optimize resource utilization.